A
Anette Duensing
Researcher at University of Pittsburgh
Publications - 71
Citations - 5945
Anette Duensing is an academic researcher from University of Pittsburgh. The author has contributed to research in topics: Imatinib mesylate & Centrosome. The author has an hindex of 30, co-authored 69 publications receiving 5519 citations. Previous affiliations of Anette Duensing include Brigham and Women's Hospital.
Papers
More filters
Journal ArticleDOI
Actin-binding protein profilin1 promotes aggressiveness of clear-cell renal cell carcinoma cells
Abigail Allen,David Gau,Paul G. Francoeur,Jordan Sturm,Yue Wang,Ryan Martin,Jodi K. Maranchie,Anette Duensing,Adam Kaczorowski,Stefan Duensing,Lily Wu,Michael T. Lotze,David Ryan Koes,Walter J. Storkus,Partha Roy +14 more
TL;DR: Treatment with a novel computationally designed Pfn1–actin interaction inhibitor identified herein reduces proliferation and migration of RCC cells in vitro and RCC tumor growth in vivo and proposes a potentiating role for Pfn 1 in promoting tumor cell aggressiveness in the setting of ccRCC.
Journal ArticleDOI
Differential antitumor activity of compounds targeting the ubiquitin-proteasome machinery in gastrointestinal stromal tumor (GIST) cells.
Jessica L. Rausch,Areej A. Ali,Donna M. Lee,Yemarshet K. Gebreyohannes,Keith R. Mehalek,Aya Agha,Sneha S. Patil,Yanis Tolstov,Jasmien Wellens,Harbir S. Dhillon,Kathleen R. Makielski,Maria Debiec-Rychter,Patrick Schöffski,Agnieszka Wozniak,Anette Duensing +14 more
TL;DR: 20S proteasome inhibitors are confirmed as promising strategy to overcome TKI resistance in GIST, while highlighting the complexity of the ubiquitin-proteasome machinery as a therapeutic target.
Journal ArticleDOI
Opposing roles of KIT and ABL1 in the therapeutic response of gastrointestinal stromal tumor (GIST) cells to imatinib mesylate
Jessica L. Rausch,Sergei Boichuk,Areej A. Ali,Sneha S. Patil,Lijun Liu,Donna M. Lee,Matthew F. Brown,Kathleen R. Makielski,Ying Liu,Takahiro Taguchi,Shih-Fan Kuan,Anette Duensing +11 more
TL;DR: It is demonstrated that depletion of KIT in conjunction with ABL1 – hence mimicking imatinib treatment – leads to reduced apoptosis induction and attenuated inhibition of cellular proliferation when compared to depletion ofKIT alone.
Journal ArticleDOI
Genomic features of renal cell carcinoma with venous tumor thrombus
Gregor Warsow,Daniel Hübschmann,Daniel Hübschmann,Daniel Hübschmann,Kortine Kleinheinz,Kortine Kleinheinz,Cathleen Nientiedt,Martina Heller,Laura Van Coile,Yanis Tolstov,Lukas Trennheuser,Kathrin Wieczorek,Carine Pecqueux,Claudia Gasch,Timur H. Kuru,Timur H. Kuru,Joanne Nyarangi-Dix,Gencay Hatiboglu,Dogu Teber,Sven Perner,Albrecht Stenzinger,Wilfried Roth,Wilfried Roth,Boris Hadaschik,Boris Hadaschik,Sascha Pahernik,Sascha Pahernik,Dirk Jäger,Carsten Grüllich,Anette Duensing,Roland Eils,Roland Eils,Matthias Schlesner,Holger Sültmann,Markus Hohenfellner,Stefan Duensing +35 more
TL;DR: In this article, the authors applied multiregion whole exome sequencing to a total of 37 primary tumor and venous tumor thrombus (VTT) samples including normal tissue specimens from five consecutive patients.
Journal ArticleDOI
High prevalence of DNA damage repair gene defects and TP53 alterations in men with treatment-naïve metastatic prostate cancer –Results from a prospective pilot study using a 37 gene panel
Cathleen Nientiedt,Volker Endris,Maximilian Jenzer,Josef Mansour,Nassim Tawanaie Pour Sedehi,Carine Pecqueux,Anna-Lena Volckmar,Jonas Leichsenring,Olaf Neumann,Martina Kirchner,Shirin Hoveida,Philippa Lantwin,Katrin Kaltenecker,Svenja Dieffenbacher,Claudia Gasch,Luisa Hofer,Desiree Franke,Georgi Tosev,Magdalena Görtz,Viktoria Schütz,Jan-Philipp Radtke,Joanne Nyarangi-Dix,Gencay Hatiboglu,Tobias Simpfendörfer,Gita Schönberg,Sanjay Isaac,Dogu Teber,Stefan A. Koerber,Georgia Christofi,Elena Czink,Rebecca Kreuter,Leonidas Apostolidis,Clemens Kratochwil,Frederik L. Giesel,Uwe Haberkorn,Jürgen Debus,Holger Sültmann,Stefanie Zschäbitz,Dirk Jäger,Anette Duensing,Peter Schirmacher,Carsten Grüllich,Markus Hohenfellner,Albrecht Stenzinger,Stefan Duensing +44 more
TL;DR: The results indicate that this approach can detect actionable DNA repair gene alterations, uncommon mutations as well as mutations associated with therapy resistance in a high number of patients, in particular patients with treatment-naïve metastatic prostate cancer.